Forte Biosciences, Inc. Balance Sheet
FBRX|2 years of annual SEC 10-K data (FY2018-FY2019)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$28M
FY2019
Cash
$41M
Cash and equivalents
Total Debt
N/A
FY2019
Shareholder Equity
$58M
FY2019
Forte Biosciences, Inc. had $28M in total assets and $58M in shareholders' equity as of FY2019.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 |
|---|---|---|
| Cash & Equivalents | $40.8M | $5.5M |
| Current Assets | $23.0M | $97.7M |
| PP&E (Net) | $1.7M | $4.0M |
| Total Assets | $28.2M | $103.1M |
| Current Liabilities | $13.2M | $16.5M |
| Total Debt | - | $26.2M |
| Shareholders' Equity | $58.1M | -$124.4M |